THE INVESTOR

메뉴열기

Celltrion’s Truxima hits Germany

PUBLISHED : May 18, 2017 - 14:55

UPDATED : May 18, 2017 - 14:55

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Korean biopharmaceutical firm Celltrion said on May 18 that its biosimilar drug Truxima has started sales in Germany.

Global firm Mundipharma International began distributing Celltrion’s biosimilar to Roche’s Mabthera in the country, Celltrion said.

In February, the European Medicines Agency accepted Celltrion’s application to sell the antibody biosimilar, which is used in the treatment of a number of diseases, including rheumatoid arthritis and non-Hodgkin‘s lymphoma, a type of leukemia.

Celltrion hit the British shelves last month, the first European country.

“In Germany, Truxima’s original drug is the most expensive among the European countries. The company believes that Truxima will be competitive in terms of the price,” said a Celltrion official who declined to be named.

By Alex Lee and newswires (alexlee@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
JUVENILE PROTECTION MANAGER : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.